Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (Q35033377)

5 August 2017

title

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (English)

1 reference

5 August 2017

3

1 reference

5 August 2017

11

1 reference

5 August 2017

Corrado Caracò

6

0 references

Gerardo Botti

series ordinal

5

object named as

Gerardo Botti

1 reference

5 August 2017

Paolo Antonio Ascierto

series ordinal

4

object named as

Paolo A Ascierto

1 reference

5 August 2017

1

Antonella Manca

1 reference

Antonio Giuseppe Maria Cossu

5 August 2017

series ordinal

10

object named as

Antonio Cossu

1 reference

5 August 2017

8

Maria Colombino

1 reference

5 August 2017

9

MariaCristina Sini

1 reference

5 August 2017

2

Amelia Lissia

1 reference

5 August 2017

7

Ignazio Stanganelli

1 reference

5 August 2017

publication date

28 January 2015

1 reference

Journal of Translational Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

13

1 reference

5 August 2017

page(s)

37

1 reference

Creative Commons Attribution 4.0 International

5 August 2017

copyright license

start time

28 January 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12967-015-0401-8

0 references

cites work

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Melanoma resistance: a bright future for academicians and a challenge for patient advocates

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Resistance to RAF inhibitors revisited

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Novel somatic mutations to PI3K pathway genes in metastatic melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

A landscape of driver mutations in melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

8 July 2018

Main roads to melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

A novel AKT3 mutation in melanoma tumours and cell lines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Distinct sets of genetic alterations in melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Akt-dependent transformation: there is more to growth than just surviving

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Mutations of the BRAF gene in human cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4312444

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0401-8

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0401-8

BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0401-8

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0401-8

PI3-kinase subunits are infrequent somatic targets in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12967-015-0401-8

Multiple synchronous cutaneous melanomas: implications for prevention

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25627962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mutations of PIK3CA are rare in cutaneous melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25627962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S12967-015-0401-8

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference